Skip to main content

CD79b-19 CAR T cells

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

  • RegistryNCT06026319
  • PhasePhase 1
  • StatusRecruiting
  • ConditionNon-hodgkin Lymphoma
  • SponsorMarcela V. Maus, M.D.,Ph.D.
How CD79b-19 CAR T cells worksNCT060263191 min

What the film says

Read the transcript

This trial is for relapsed or refractory non Hodgkin lymphoma, in adults.

The idea: bivalent CAR T cells that aim at two targets, CD79b and CD19, instead of one. White blood cells are collected, then three days of chemotherapy lower the number of lymphocytes, then the CAR T cells are given by vein in a single infusion.

This phase 1 study plans 24 patients and tracks side effects and dose limiting toxicity. At Massachusetts General Hospital in Boston, Matthew Frigault leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT06026319

    Relapsed or refractory non Hodgkin lymphoma, adults; CAR T cells aimed at two targets, CD79b and CD19; White blood cells collected, three days of chemotherapy to lower lymphocytes, then a single infusion by vein; Phase 1, 24 patients, side effects and dose limiting toxicity (+1 more lines)

The drug

What is being tested.

This is a two-part, non-randomized, open label, single-site Phase 1 study of CD79b-19 CAR T cells as a treatment for relapsed/refractory Non-Hodgkin Lymphoma.

This study consists of 2 parts: * Part A (Dose Escalation): The investigators are looking to find the highest dose of the study intervention that can be administered safely without severe or unmanageable side effects, not everyone who participates in this research study will receive the same dose of the study intervention. The dose given will depend on the number of participants who have been enrolled prior and how well the dose was tolerated.

The study

How the trial runs.

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Voluntarily sign informed consent form(s)
  • ≥18 years of age at the time of signing informed consent
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky ≥60%, see Appendix A)
  • Diagnosis of histologically or cytologically confirmed relapsed/refractory (R/R) Non Hodgkins lymphoma as defined as one of the following (Note: only patients with indolent lymphomas that warrant treatment should be treated, this will include those with local symptoms due to progressive/bulky disease, compromised organ function, B symptoms, extra-nodal disease, cytopenias from marrow involvement and/or in the opinion of the treating physician believe that any of the above symptoms or potentially life threatening involvement will occur will be treated):
  • Follicular Lymphoma (FL) grade 1, grade 2, or grade 3a
  • 1. R/R disease after 2 or more prior lines of systemic therapy

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.